Literature DB >> 9230637

Effects of the postpartum period on nortriptyline pharmacokinetics.

K L Wisner1, J M Perel, K S Peindl, R L Findling, B H Hanusa.   

Abstract

The objective of this research was to investigate sequential serum levels and level/dose ratios of the tricyclic antidepressant nortriptyline (NTP) through the first 17 postpartum weeks. The initial NTP dose was given immediately postpartum to 16 mothers and increased gradually to 70 mg over the first week. A dose of 75 mg was prescribed until adjustment according to serum levels. Serum levels of NTP and its metabolites Z- and E-OH-NTP were determined. At postpartum Week 2, the women developed a mean level/dose (L/D) ratio for NTP of 1.11 (range 0.37 to 3.23), and subsequently experienced an increase in the L/D ratios which continued through Week 6. At Week 8, the NTP L/D ratios declined, and became relatively stable at Week 11 and beyond. For postpartum women treated with NTP, side effect profiles should be carefully followed during the first 6 weeks after delivery as a clinical marker for elevation of serum levels. Since our highest L/D ratios for NTP occurred at Week 6, a serum level is recommended at this time. If the dose needs to be lowered to maintain a nontoxic level, a repeat serum level should be obtained at Week 11, at which time an increase in dose may be required.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9230637

Source DB:  PubMed          Journal:  Psychopharmacol Bull        ISSN: 0048-5764


  12 in total

Review 1.  Depression in childbearing women: when depression complicates pregnancy.

Authors:  Sheila M Marcus; Julie E Heringhausen
Journal:  Prim Care       Date:  2009-03       Impact factor: 2.907

2.  Mother-infant antidepressant concentrations, maternal depression, and perinatal events.

Authors:  Dorothy Sit; James M Perel; Stephen R Wisniewski; Joseph C Helsel; James F Luther; Katherine L Wisner
Journal:  J Clin Psychiatry       Date:  2011-07       Impact factor: 4.384

Review 3.  Psychotropic Treatment During Pregnancy: Research Synthesis and Clinical Care Principles.

Authors:  Hannah K Betcher; Katherine L Wisner
Journal:  J Womens Health (Larchmt)       Date:  2019-12-03       Impact factor: 2.681

4.  Disposition of chiral and racemic fluoxetine and norfluoxetine across childbearing.

Authors:  Dorothy Sit; James M Perel; James F Luther; Stephen R Wisniewski; Joseph C Helsel; Katherine L Wisner
Journal:  J Clin Psychopharmacol       Date:  2010-08       Impact factor: 3.153

Review 5.  Pharmacotherapy for mood disorders in pregnancy: a review of pharmacokinetic changes and clinical recommendations for therapeutic drug monitoring.

Authors:  Kristina M Deligiannidis; Nancy Byatt; Marlene P Freeman
Journal:  J Clin Psychopharmacol       Date:  2014-04       Impact factor: 3.153

6.  When depression complicates childbearing: guidelines for screening and treatment during antenatal and postpartum obstetric care.

Authors:  Maria Muzik; Sheila M Marcus; Julie E Heringhausen; Heather Flynn
Journal:  Obstet Gynecol Clin North Am       Date:  2009-12       Impact factor: 2.844

7.  Changes in antidepressant metabolism and dosing across pregnancy and early postpartum.

Authors:  Dorothy K Sit; James M Perel; Joseph C Helsel; Katherine L Wisner
Journal:  J Clin Psychiatry       Date:  2008-04       Impact factor: 4.384

8.  Pharmacologic evidence to support clinical decision making for peripartum methadone treatment.

Authors:  D L Bogen; J M Perel; J C Helsel; B H Hanusa; M Romkes; T Nukui; C R Friedman; K L Wisner
Journal:  Psychopharmacology (Berl)       Date:  2012-08-25       Impact factor: 4.530

9.  Returning to tricyclic antidepressants for depression during childbearing: clinical and dosing challenges.

Authors:  Lauren M Osborne; Catherine A Birndorf; Lauren E Szkodny; Katherine L Wisner
Journal:  Arch Womens Ment Health       Date:  2014-03-26       Impact factor: 3.633

10.  The impact of pregnancy on the pharmacokinetics of antidepressants: a systematic critical review and meta-analysis.

Authors:  Georgios Schoretsanitis; Olav Spigset; Julia C Stingl; Kristina M Deligiannidis; Michael Paulzen; Andreas A Westin
Journal:  Expert Opin Drug Metab Toxicol       Date:  2020-04-10       Impact factor: 4.481

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.